Form 4 for KURA Kura Oncology, Inc.
Accepted 2026-01-06 00:00:00 ET · period of report 2026-01-02 · accession 0001193125-26-004569 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-06 | 2026-01-02 | KURA | DOYLE THOMAS JAMES | SVP, Fin, Accounting | A - Grant | $0.00 | +21.2K | 152.3K | +16% | $0 |
| D | 2026-01-06 | 2026-01-02 | KURA | DOYLE THOMAS JAMES | SVP, Fin, Accounting | A - Grant | $0.00 | +42.5K | 42.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-02 | A | A | 21,250 | $0.00 | 152,309 | D | — | — | (F1) Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/27, 1/26/28, 1/26/29 and 1/26/30. (F2) Includes 802 shares acquired on November 17, 2025 pursuant to the Issuer's Employee Stock Purchase Plan. |
| 2 | Derivative | Option to purchase common stock | 2026-01-02 | A | A | 42,500 | $0.00 | 42,500 | D | $10.34 · — to 2036-01-01 | 42,500 Common Stock | (F3) This option vests in 48 equal monthly installments commencing on the grant date. |